Daily Intelligence Brief
Depo-Provera MDL Absorbs 518 Filings In Week-Long Surge As Meningioma Claims Accelerate
The Depo-Provera Products Liability Litigation (MDL 3140) (N.D. Fla., Judge M. Casey Rodgers) has exploded with 518 new filings over the past seven days, cementing its position as the most active emerging mass tort in the federal system. The surge includes concentrated blocks from March 14-15, with individual cases such as Celesta F. Barton v. Pfizer Inc. (3:26-cv-01939) and Aisha W. Frazier v. Pfizer Inc. (3:26-cv-01934) leading a wave of meningioma claims against the birth control manufacturer. OnderLaw LLC continues to drive volume with bulk filings, following similar patterns seen in previous weeks. The litigation's rapid consolidation pace suggests Judge Rodgers will face mounting pressure to issue case management protocols and bellwether selection timelines within the next 60 days.Uber Sexual Assault MDL Adds 51 Cases As $63M Verdict Fuels Liability Expansion
MDL 3084 (N.D. Cal.) absorbed 51 new sexual assault complaints in the past week, including Jane Roe CL 289 v. Uber Technologies, Inc. (3:26-cv-02288) and Jane Doe LS 691 v. Uber Technologies, Inc. (3:26-cv-02326), as a recent $63 million California state court verdict against the ride-share giant raises the stakes for federal coordination. The March 20 verdict, reported by The Legal Examiner, marks one of the largest individual assault awards against Uber and is already being cited in federal pleadings to counter corporate liability defenses. The MDL now faces critical questions about whether Uber's background check protocols and driver monitoring systems constitute actionable negligence under federal pleading standards, with the state verdict potentially serving as a damages benchmark for bellwether selection.Ozempic Gastroparesis MDL Sees 44 New Filings As Parallel NAION Claims Emerge
Novo Nordisk and Eli Lilly face intensifying bifurcated pressure as MDL 3094 (E.D. Pa., Judge Karen Marston) added 44 gastroparesis claims including McDowell v. Novo Nordisk A/S (2:26-cv-02684) and Rae Ramshaw v. Novo Nordisk A/S (2:26-cv-01697), while a separate vision-loss MDL (MDL 3163) logged two additional NAION cases. The gastroparesis docket's steady volume—now spanning hundreds of claims—contrasts with the emerging optic neuropathy litigation, which remains in early consolidation but shares overlapping discovery into GLP-1 mechanism of action. Judge Marston's coordination of both dockets creates potential efficiency gains for plaintiffs' counsel but also risks defense arguments that distinct injury pathways require separate expert and causation tracks. The filing pace suggests Daubert motion practice will dominate the latter half of 2026.Generated by LexGenius Feed. Signals sourced from PACER federal court dockets, FDA/OpenFDA adverse event database, Federal Register, PubMed, and Google News.
